Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib

Exclusion Criteria

• •Patients who have had chemotherapy, radiotherapy, experimental therapy or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered (to grade -Patients may not be receiving any other investigational agents.
• •Patients with prior anti-VEGF directed therapy may be allowed only if approved by the PI and greater than 8 weeks since last exposure
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to axitinib
• •Patients with poorly controlled hypertension
• •Patients who require use of therapeutic doses of coumarin-derivative anticoagulants
• •Patients with any condition that impairs their ability to swallow and retain axitinib tablets are excluded.
• •Patients with any of the following conditions are excluded: Serious or nonhealing wound, ulcer, or bone fracture; History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment; Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry; History of myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry; History of pulmonary embolism within the past 12 months; Class III or IV heart failure as defined by the NYHA functional classification system.
• •Patients without appropriate lesion on CT scan for FLT-PET/CT imaging
• •CYP3A4 inducers/inhibitors medications will be reviewed by the Principal Investigator.
• •Steroid use is not recommended during axitinib treatment
• •Patients with a pre-existing thyroid abnormality who are unable to maintain thyroid function in the normal range with medication are ineligible.
• •Patients with known brain metastases should be excluded
• •HIV-positive patients on combination antiretroviral therapy are ineligible